Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a ...
Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months. Nasdaq said the company will rejoin the Nasdaq-100 before the open on October ...
Morning Overview on MSN
The first mRNA flu vaccine is cleared for adults 50 and older this season
Moderna’s mFlusiva is the seasonal influenza shot that replaces the traditional egg-grown or cell-grown virus protein with a ...
The bet is a public-private partnership among the NIH, the nonprofit Foundation for the NIH, researchers, drug and biotech ...
Moderna Inc. stocks have been trading up by 10.78 percent on optimism surrounding its latest mRNA vaccine developments. Key ...
Moderna Inc. stocks have been trading up by 12.29 percent after strong mRNA pipeline progress fueled bullish investor ...
The FDA’s approval of an mRNA flu shot presents a new, long-awaited option—and raises big questions about the future of flu ...
Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.
The U.S.-approved vaccine — faster to produce and more precise than traditional flu shots — is awaiting the green light in Canada ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results